Sartorius Stedim Biotech SA: HALF-YEAR report of the liquidity contract with the stockbroker company Gilbert Dupont
02-Jul-2019 / 12:08 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Sartorius Stedim Biotech S.A. - 13781 Aubagne, France
Half-year report of the liquidity contract with the stockbroker company
Gilbert Dupont
Aubagne, France | July 2, 2019
Under the liquidity contract concluded between SARTORIUS STEDIM BIOTECH and
the stockbroker Gilbert Dupont, the following assets appeared on the liquidity
account on June 28, 2019:
- Number of shares: 2,519
- Liquidity account cash balance: EUR468,433.16
During the first half of 2019, the following were negotiated:
ORDER INTAKE 72,168 securities EUR7,778,802.4 2,404 transactions
3
SALES 73,065 securities EUR7,889,953.1 2,522 transactions
0
It should be noted that in the second half of 2018, which ended December 31,
2018, the following assets appeared on the liquidity account:
- Number of shares: 3,416
- Liquidity account cash balance: EUR357,282.50
It should also be noted that upon implementing the liquidity contract, the
following assets were made available:
- Number of shares: 654
- Liquidity account cash balance: EUR394,895.12
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the
biopharmaceutical industry. As a total solutions provider, the company helps
its customers to manufacture biotech medications safely, rapidly and
economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is
quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D
sites in Europe, North America and Asia and an international network of sales
companies, Sartorius Stedim Biotech has a global reach. The Group has been
annually growing by double digits on average and has been regularly expanding
its portfolio by acquisitions of complementary technologies. In 2018, the
company earned sales revenue of EUR1,212.2 million and currently employs some
5,800 people.
______________________________________________________________________________
___________
Contact
Ben Orzelek
Investor Relations
+49(0)551.308.1668
ben.orzelek@sartorius.com
Sartorius Stedim Biotech SA
Z.I. Les Paluds
Avenue de Jouques, CS 91051
13781 Aubagne Cedex, France
Phone: +33.(0)4.42.84.56.00
Fax: +33.(0)4.42.84.56.19
www.sartorius-stedim.com
Regulatory filing PDF file
Document title: HALF-YEAR report of the liquidity contract with the
stockbroker company Gilbert Dupont
Document: http://n.eqs.com/c/fncls.ssp?u=CRTGAYKIHJ [1]
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: info@sartorius-stedim.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext Ticker: DIM
AMF Category: Share buyback / Disposal of own shares / Information
relating to the liquidity contract
EQS News ID: 834751
End of Announcement EQS News Service
834751 02-Jul-2019 CET/CEST
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=2c8b56d6fb473e3a70fd329eb0cfecf4&application_id=834751&site_id=vwd&application_name=news
(END) Dow Jones Newswires
July 02, 2019 06:08 ET (10:08 GMT)
© 2019 Dow Jones News
